-
Most Recent
Search Results
240 results for fsa
FDA Issues Warning on Hepatitis C Drugs
The Food and Drug Administration (FDA) has issued a warning surrounding several Hepatitis C drugs such as Sovaldi, Harvoni and Gilead Sciences.
Bear of the Day: Agrium Inc. (USA) (AGU)
Agrium (AGU) stock is in trouble, especially when you consider the fertilizer industry’s long-lasting struggles and gloomy outlook.
FDA Approves Ecstasy Trials for PTSD Sufferers
The Food and Drug Administration (FDA) has approved clinical trials for ecstasy to treat PTSD sufferers, including police and firefighters.
PSA Priced to Perfection in a Highly Competitive Industry
PSA is a well-run and financially strong company that will see increased earnings into 2015, but those expectations are already priced in.
FDA Approves 41 New Drugs in 2014
The FDA has approved 41 new drugs in 2014–the highest tally since 1996. The list includes 15 drugs for rare diseases.
Tesla’s Public FSD Beta Is A Huge Mistake
Tesla is risking its reputation and brand value by having customers beta test its driverless software. Tesla stock could take a hit.
Why Is Fisker (FSR) Stock Up Today?
The electric vehicle startup’s stock is marching higher on positive news related to preorders of its SUV and news of expanded production.
FDA Considers Giving OK for OTC Singulair
Drug company Merck is looking for approval from the Food and Drug Administration to start selling its Singulair over the counter.
USA TODAY Gets a Facelift at Age 30
Gannett’s flagship newspaper USA TODAY — America’s second-largest daily print publication — will sport a new redesign for its 30th birthday.
FDA, Insurers Demand Tests for New Drugs
Pressure on pharmaceutical companies for evidence that their drugs work is fueling a surge in the global market for “companion diagnostics.”
Ranbaxy Closes In on FDA Approval for Generic Lipitor
Ranbaxy could sell $650 million worth of the drug in its first 180 days. But Pfizer is battling hard to keep branded Lipitor alive.
Gannett’s USA Today Resumes Deal with Starbucks
As of this week, Starbucks (SBUX) has started offering copies of USA Today to its java-drinking customers. The flagship paper of media giant Gannett (GCI),…
FSR Stock Alert: Is Fisker on the Brink of Bankruptcy
FSR stock is plunging about 45% after Fisker reportedly hired a consulting firm to help the automaker with a possible bankruptcy filing.
The 5 Biggest Buyers of Fisker (FSR) Stock
FSR stock isn’t popular among institutional investors. These investors, as well as hedge funds, were net sellers of Fisker during Q4.
Ocugen Stock Still Looks Poised to Tumble
Ocugen’s apparent failure to prepare a U.S. trial for Covaxin, which will likely be necessary for FDA approval, bodes badly for OCGN stock.
Try a Small Position in Fisker Stock, but Monitor the EV Competition
Unless this electric vehicle manufacturer can rise above the rest, it’s going to be increasingly tough to defend a position in FSR stock.
Trade of the Day: ASA Ltd. Offering Attractive Entry Point
The recent pullback on profit-taking may be a good opportunity to buy ASA for the longer-term.
Feature-Rich Cars Could Power Fisker Stock to the Next Level
Even as FSR stock seeks direction, Fisker continue to move forward with truly unique, tech-enhanced and environmentally friendly vehicles.
Fisker Is Working to Become a Heavenly Investment
Patience is a needed for owning FSR stock, but an optional collar spread should be required business for today’s investors
Ben & Jerry’s CBD Ice Cream Is Coming: 11 Things We Know
Ben & Jerry’s CBD ice cream is in the works, but isn’t available yet due to some restrictions from the U.S. Food and Drug Administration.
Why Is Outlook Therapeutics (OTLK) Stock Down 78% Today?
Outlook Therapeutics (OTLK) stock is taking a beating on Wednesday after getting a rejection letter from the FDA for its wet AMD treatment..
GMO Salmon: Genetically Engineered Fish Fights for Place on Your Plate
After four years of debate, the FDA still hasn’t approved the commercial sale of GMO salmon, and doesn’t appear to be near a final decision.
Inovio Has Little to Show for Its Covid-19 Efforts
Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.
9 – 10 of 240 results
